Novartis heart drug poised to reach blockbuster status

Jan 24, 2018

A Novartis medication aimed at treating heart failure could become a blockbuster, according to a company executive.

The medication, called Entresto, was released in 2015 and brought in $507 million revenue. But because demand for the drug could skyrocket, the company now predicts that Entresto will rake in about $4-$5 billion in annual revenue. 

Blockbusters are defined as a drug that brings in at least $1 billion in annual sales.

Novartis also has the drug in a trial to see if it could become a treatment for preserved ejection fraction, another type of heart failure.

Read the full Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments